Author: slightbourne@noblecapitalmarkets.com

Graham (GHM) – A Solid 2Q26

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, November 11, 2025

Graham Corporation designs, manufactures and sells critical equipment for the energy, defense and chemical/petrochemical industries. The Company designs and manufactures custom-engineered ejectors, vacuum pumping systems, surface condensers and vacuum systems. It is a nuclear code accredited fabrication and specialty machining company. It supplies components used inside reactor vessels and outside containment vessels of nuclear power facilities. Its equipment is found in applications, such as metal refining, pulp and paper processing, water heating, refrigeration, desalination, food processing, pharmaceutical, heating, ventilating and air conditioning. For the defense industry, its equipment is used in nuclear propulsion power systems for the United States Navy. The Company’s products are used in a range of industrial process applications in energy markets, including petroleum refining, defense, chemical and petrochemical processing, power generation/alternative energy and other.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Graham put up solid results for the second quarter of fiscal 2026. The Company executed well across all the business lines, driving broad based-growth. Demand across the end markets remains healthy, and the Defense and Space markets continue to see robust activity.

2Q26 Results.  Revenue grew 23% to $66 million, driven by solid performance across all end markets. We were at $59 million. Adjusted EBITDA was $6.3 million, up 12% from the prior year, and adjusted EBITDA margin was 9.5%. We had forecasted $6.2 million and 10.4%. Net income for the quarter was $0.28 per diluted share, and adjusted net income was $0.31 per diluted share. We were at $0.30 and $0.32, respectively.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – Third Quarter Results Exceed Expectations

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, November 11, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third quarter results. RAIL generated third-quarter adj. net income of $7.8 million, or $0.24 per share, compared to $7.3 million, or $0.08 per share, during the prior year period. We had forecast net income of $5.6 million, or $0.16 per share. Rail car deliveries were 1,304 units compared to 961 units during the prior year period. Third-quarter gross margin increased to 15.1% compared to 14.3% during the prior year period. Adjusted EBITDA increased 56.1% to $17.0 million, representing a margin of 10.6%, compared to $10.9 million and a margin of 9.6% in the third quarter of 2024. 

Updated corporate guidance. While management still expects 2025 rail car deliveries in the range of 4,500 to 4,900 and adjusted EBITDA in the range of $43 million to $49 million, revenue expectations were lowered to a range of $500 million to $530 million from $530 million to $595 million. Revised revenue expectations reflect changes in the product mix due to a greater number of conversion rail cars versus new rail cars in the second half.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SoftBank Sells $5.8 Billion Nvidia Stake to Fuel Expanding AI Ambitions

Posted on by slightbourne@noblecapitalmarkets.com

SoftBank Group Corp. has sold its entire stake in Nvidia Corp. for $5.83 billion, marking another major move by founder Masayoshi Son to fund his growing ambitions in artificial intelligence. The sale underscores SoftBank’s shift toward becoming a central player in the AI ecosystem—one that spans data centers, chip design, robotics, and advanced cloud infrastructure.

The decision to sell Nvidia shares comes as global investors question whether massive AI spending—expected to exceed $1 trillion by companies like Meta Platforms and Alphabet—will produce long-term profits. Despite this uncertainty, Son continues to double down on AI, redirecting proceeds into projects such as Stargate, a mega data center venture being developed in collaboration with OpenAI and Oracle Corp.

SoftBank’s U.S.-listed shares rose more than 7% following the announcement, while Nvidia’s stock slipped over 3% during trading on Tuesday. The move illustrates the shifting balance of investor sentiment as capital flows from established AI leaders toward emerging infrastructure and hardware bets.

According to SoftBank executives, the Nvidia sale was not due to concerns about the chipmaker but rather a strategic move to free up capital. Chief Financial Officer Yoshimitsu Goto emphasized that the proceeds will be used to finance new AI initiatives, though he declined to comment on whether the sector is currently in a bubble.

This is not the first time SoftBank has exited Nvidia. The company sold its previous stake in 2019, only to re-enter the stock in 2020—just before Nvidia’s meteoric rise fueled by the AI boom. By March 2025, SoftBank had quietly accumulated a $3 billion position in Nvidia, which has since surged by more than $2 trillion in market value amid the global AI frenzy.

The timing of the sale proved highly profitable for SoftBank. The company recently reported a ¥2.5 trillion ($16.2 billion) net income for its fiscal second quarter, driven by its holdings in OpenAI, Arm Holdings, and other AI-focused firms. Analysts expect SoftBank to post its strongest annual profit since 2020, with the Nvidia sale adding significant liquidity to support its ongoing expansion.

Son’s AI roadmap is ambitious. In addition to the Stargate data center network, SoftBank is pursuing a $1 trillion AI manufacturing hub in Arizona, potential collaborations with Taiwan Semiconductor Manufacturing Co. (TSMC), and the acquisition of Ampere Computing LLC for $6.5 billion. The company has also agreed to purchase ABB Ltd.’s robotics division for $5.4 billion—moves that signal a vertically integrated AI empire in the making.

SoftBank’s financial strategy has been equally bold. It recently expanded its margin loan backed by Arm shares to $20 billion, secured an $8.5 billion bridge loan for its OpenAI investment, and committed the full $22.5 billion originally pledged to the AI startup.

The Japanese conglomerate’s stock has surged nearly 78% over the past quarter, its best performance in two decades. The company also announced a 4-for-1 stock split effective January 1, 2026, aimed at making its shares more accessible to retail investors.

As Son pushes deeper into the AI frontier, SoftBank’s latest divestment highlights both opportunity and risk. While the Nvidia exit frees billions for new ventures, it also removes exposure to one of the most successful AI chipmakers of the decade. Still, for Masayoshi Son, the message is clear: SoftBank’s future lies not in following AI’s leaders, but in building the infrastructure that powers them.

Dow Surges 500 Points as Investors Rotate Out of Tech and Into Value Plays

Posted on by slightbourne@noblecapitalmarkets.com

The Dow Jones Industrial Average rallied more than 500 points on Tuesday as investors shifted money away from high-flying technology stocks and toward value-oriented sectors, extending a broader trend of portfolio rotation that’s been building for weeks.

The 30-stock blue-chip index climbed 542 points, or roughly 1.2%, driven by gains in healthcare and industrial names such as Merck, Amgen, and Johnson & Johnson. The S&P 500 edged higher by 0.3%, while the Nasdaq Composite slipped 0.2% as pressure continued to mount on the technology sector.

The day’s market action reflected an ongoing tug-of-war between growth and value equities. While tech stocks have dominated 2025’s rally, recent concerns about stretched valuations have led investors to lock in profits and reallocate capital toward sectors considered more resilient in a high-rate, slower-growth environment.

The AI sector was among the hardest hit. Cloud infrastructure provider CoreWeave sank 16% after issuing disappointing guidance, sparking a broader selloff in artificial intelligence names. Nvidia dropped 2% following reports that SoftBank exited its multibillion-dollar position in the chipmaker, while Micron, Oracle, and Palantir also traded lower. The Technology Select Sector SPDR Fund (XLK) finished the session down about 1%.

Meanwhile, value-oriented sectors like healthcare, energy, and consumer staples gained traction as investors sought stability amid lingering economic uncertainty. Analysts noted that companies with strong balance sheets, consistent earnings, and solid dividends are becoming increasingly attractive as the market recalibrates after an AI-driven surge earlier this year.

The broader sentiment was also supported by optimism that the record-setting U.S. government shutdown may soon end. The Senate passed a bill Monday evening to reopen the government, with the measure now awaiting approval in the House. The latest version of the bill excludes an extension of Affordable Care Act subsidies but includes provisions for a vote on the issue in December.

While the political gridlock has weighed on sentiment in recent weeks, hopes for resolution boosted cyclical sectors that tend to benefit from improved government spending and consumer confidence.

Still, not all economic data aligned with the upbeat tone in equities. A new ADP report showed a slowdown in private-sector job creation for the four weeks ending October 25, falling by more than 11,000 per week on average. Combined with muted hiring trends and rising layoff announcements, the data suggest a softer labor market heading into year-end.

Even so, investors appear willing to look past the near-term softness in economic indicators in favor of more stable growth plays. The move away from richly valued technology stocks toward defensive and dividend-paying equities signals that Wall Street may be entering a new phase of this market cycle—one less driven by momentum and more by fundamentals.

At the close of trading, the Dow stood at its highest level in over two months, marking a strong rebound from October’s volatility. As traders continue to rotate portfolios, the key question heading into the final weeks of 2025 is whether this shift toward value and quality will persist—or if tech’s dominance will once again reassert itself.

TreeHouse Foods to Be Acquired by Investindustrial in $2.9 Billion Deal

Posted on by slightbourne@noblecapitalmarkets.com

TreeHouse Foods, a leading U.S. private-label snacking and beverage manufacturer, has entered into a definitive agreement to be acquired by Investindustrial, a European investment group, in a transaction valued at $2.9 billion. The all-cash deal marks a significant milestone for TreeHouse Foods as it transitions from a publicly traded company on the New York Stock Exchange to a privately held entity under Investindustrial’s ownership.

Under the terms of the agreement announced November 10, 2025, TreeHouse shareholders will receive $22.50 per share in cash and one non-transferable Contingent Value Right (CVR) per share. The CVR provides shareholders the opportunity to receive a portion of any net proceeds from ongoing litigation related to TreeHouse’s former coffee business. The cash portion values TreeHouse’s equity at approximately $1.2 billion, representing a 38 percent premium over the company’s closing price on September 26, 2025, and a 29 percent premium over its 30-day volume-weighted average.

The acquisition underscores TreeHouse’s strategic evolution over the past several years toward becoming a focused snacking and beverage private brand leader. The company has streamlined its portfolio to concentrate on high-growth, high-margin categories such as nuts, cookies, pretzels, and beverages. The sale to Investindustrial is expected to provide immediate value to shareholders while positioning the company for continued growth under private ownership.

Investindustrial, known for its strong track record in food and beverage investments, views TreeHouse as an important addition to its expanding North American portfolio. Following the transaction, Investindustrial portfolio companies will collectively operate more than 85 manufacturing plants and employ over 16,000 people across the region. The firm has emphasized that TreeHouse Foods will continue to operate independently, retaining its leadership team and brand identity.

The deal has been unanimously approved by the TreeHouse Foods Board of Directors and is expected to close in the first quarter of 2026, pending shareholder and regulatory approval. Notably, activist investor JANA Partners LLC, which holds a 10 percent stake in TreeHouse, has already agreed to vote in favor of the acquisition. The transaction is not contingent on financing, signaling strong confidence from both parties in the deal’s completion.

As part of the agreement, TreeHouse shareholders will also receive a Contingent Value Right tied to the company’s ongoing lawsuit against Keurig Green Mountain, a subsidiary of Keurig Dr Pepper. The case, filed in 2014, alleges antitrust and unfair competition practices related to single-serve coffee pods and brewers. Depending on the court’s decision, potential damages could range from hundreds of millions to over a billion dollars, with CVR holders entitled to 85 percent of any recovered proceeds.

Following the completion of the acquisition, TreeHouse Foods will delist from the NYSE and become a privately held company. The move is expected to give management greater flexibility to pursue long-term strategies without the pressures of quarterly reporting.

With Investindustrial’s backing and industry expertise, TreeHouse Foods is poised to strengthen its position in the competitive private-label market, expand its manufacturing footprint, and capitalize on the growing demand for affordable, high-quality snack and beverage products.

The GEO Group (GEO) – Solid Performance; Attractive Entry Point

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. GEO Group reported 3Q25 results at or above expectations, excluding one-time impacts. Nonetheless, the shares sold off on concerns about the pace of detentions and uncertain additional facility activations. Notably, since the beginning of the year, GEO has entered into new or expanded contracts that represent over $460 million in new incremental annualized revenues that are already under contract and are expected to normalize in 2026. This represents the largest amount of new business the Company has won in a single year in its history.

3Q25 Results. Revenue of $682.3 million rose 13.1% y-o-y. We were at $650 million. Adjusted EBITDA came in at $120.1 million, or a 17.6% margin compared to $118.6 million, or a 19.7% margin. GAAP EPS was impacted by a $232.4 million gain from the sale of Lawton and a $37.7 million non-cash charge in connection with litigation. Adjusted EPS was $0.25 versus $0.21 last year and our $0.22 estimate.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gyre Therapeutics, Inc (GYRE) – Gyre Reports 3Q25 With Several Clinical Trial Updates

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Quarter Sales Were Driven By Etuary. Gyre reported Net Income of $5.9 million or $0.04 per basic share. Revenue of $30.6 million showed year-over-year growth of 20.0%. This was driven by strength in Etuary with sales of $27.7 million. Sales of Etorel and Contiva sales were of $1.5 million and $1.2 million respectively. At the end of 3Q25 on September 30, the company had $80.3 in cash, equivalents, and securities.

The Company Made Progress In Several Important Clinical Programs. During 3Q, Gyre continued working to submit its NDA for Hydronidone approval in China. The Phase 3 trial testing Etuary in pneumonoconiosis completed enrollment, while a Phase 2/3 trial for pulmonary complications in oncology (radiation induced lung injury/pneumonitis) is planned to begin in 4Q25. The IND for a Phase 2 trial in MASH in the US is now expected to be filed in early 2026, within the timeframe we had expected.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eledon Pharmaceuticals (ELDN) – BESTOW Trial Leads To Misunderstanding of Tegoprubart Data

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 2 BESTOW Trial Data Reported. On Thursday evening, November 6, the results of the Phase 2 BESTOW trial in kidney transplant patients were presented. The trial did not meet its primary endpoint of tegoprubart superiority to the control arm but showed improvements in several important endpoints. We believe tegoprubart performed well and that the sharp decline in stock price is unwarranted.

Design Of The Phase 2 BESTOW Trial. The trial enrolled 126 patients into and randomized them into two arms. The first received tegoprubart and the second received tacrolimus, the standard of care, as a control arm. The primary endpoint was a difference in eGFR, a measure of kidney filtration and function. Additional endpoints reported were for the iBOX composite and measures of adverse events.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Twin Hospitality (TWNP) – Strategy Being Implemented

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. In the third quarter, Twin Peaks delivered a solid performance, expanding restaurant-level contribution margin to 17.0%. Sales within core markets also grew year-over-year despite regional headwinds. The conversions of certain Smokey Bones locations continues, with converted locations performing well.

3Q25 Results. Revenue decreased 1.6% y-o-y to $82.3 million, reflecting the loss of revenue from closed Smokey Bones locations as well as a decline in SSS. Twin Peaks System-wide sales declined 1.4%, with SSS off 4.1%. Adjusted EBITDA of $3 million in 3Q25 improved modestly from $2.3 million in 3Q24. Twin Hospitality reported a loss of $24.5 million compared to a net loss of $16.2 million last year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Titan International (TWI) – Some Green Shoots, Reports 3Q25

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Titan reported 3Q25 results at the high end of expectations. The Ag and EMC segments each reported revenue growth compared with the prior year period, along with expanded gross margins. The Consumer segment saw improved gross margins despite marginally lower revenues due to tariffs continuing to have some dampening effect on new equipment demand.  Notably, Titan continued to generate gross and EBITDA margins meaningfully above where they were during the last cyclical trough.

3Q25 Results. Net sales for 3Q25 were $466.5 million, compared to $448.0 million in the comparable period of 2024.  The increase was primarily driven by pricing related to passing on increases in input costs. We were at $455 million. Gross margin improved to 15.2% from 13.1%. We were at 15.2%. Adjusted EBITDA was $29.8 million in 3Q25, compared to $20.5 million in 3Q24, and our $28.5 million estimate. Adjusted EPS was $0.04 versus a loss of $0.19/sh last year and our projected $0.04/sh loss.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Saga Communications (SGA) – Influx Of Cash Likely To Fuel Stock Repurchases

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Saga Communications, Inc. is a broadcast company whose business is primarily devoted to acquiring, developing and operating radio stations. Saga currently owns or operates broadcast properties in 27 markets, including 79 FM and 33 AM radio stations. Saga’s strategy is to operate top billing radio stations in mid sized markets, defined as markets ranked (by market revenues) from 20 to 200. Saga’s radio stations employ a myriad of programming formats, including Active Rock, Adult Album Alternative, Adult Contemporary, Country, Classic Country, Classic Hits, Classic Rock, Contemporary Hits Radio, News/Talk, Oldies and Urban Contemporary. In operating its stations, Saga concentrates on the development of strong decentralized local management, which is responsible for the day-to-day operations of the stations in their market area and is compensated based on their financial performance as well as other performance factors that are deemed to effect the long-term ability of the stations to achieve financial objectives. Saga began operations in 1986 and became a publicly traded company in December 1992. The stock trades on NASDAQ under the ticker symbol “SGA”.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Results. Third quarter revenue of $28.2 million was in line with our $28.3 million estimate, representing a modest 1.8% decline against a Political advertising infused prior year period. Adj. EBITDA, excluding an extraordinary music licensing settlement expense, was $3.3 million, in line with our $3.4 million estimate. 

Q3 revenues stabilize. Excluding Political advertising, the strength in Digital advertising more than offset the weakness in its core broadcast advertising. Digital advertising was up roughly 40% in the quarter. Digital advertising continues to have strong momentum into the fourth quarter, pacing up 32%.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ONE Group Hospitality (STKS) – Third Quarter Results

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Third quarter results were below expectations as operations were impacted by factors that temporarily reduced traffic in certain markets. Rising commodity costs outpaced pricing adjustments, impacting margins. The Benihana integration continues to exceed management expectations, and the new Benihana prototype is delivering strong results.

3Q25 Results. Revenue was $180.2 million, down from $194 million in 3Q24 and our $193.5 million estimate. Adjusted EBITDA totaled $10.6 million, down from $14.9 million in 3Q24 and below our $17.6 million estimate. ONE Group reported a GAAP loss of $85.3 million, or a loss of $2.75/sh, versus a loss of $16.4 million, or $0.53/sh last year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MariMed Inc (MRMD) – Implementing the Expand the Brand Strategy

Posted on by slightbourne@noblecapitalmarkets.com


Monday, November 10, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Brand Strength. To illustrate the strength of MariMed’s brands, during the quarter in Illinois, the Company experienced a 23% sequential sales increase despite sales being down statewide 1.5%, according to Hoodie. In Massachusetts, MariMed sales increased 5% sequentially, compared to a 2% decline in the state, again according to Hoodie.

Wholesale. In terms of Wholesale, MariMed has achieved 75% penetration across all of its markets, excluding Missouri, leaving significant white space for future growth. The next step is to increase the breadth of relationship with customers, garnering additional shelf space for MariMed product.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.